SPEG

SPEG
Name	SPEG
Uniprot	Q8WWI4
Organism	Homo sapiens
Chromosome	2q35
Length	~3,000 aa

SPEG SPEG is a large striated muscle-enriched protein kinase implicated in striated muscle development and cardiac function. It is characterized by multiple serine/threonine kinase domains and long fibronectin-like regions, and has been studied across model organisms including Mus musculus, Danio rerio, Drosophila melanogaster and Xenopus laevis. Variants in the gene are associated with congenital myopathies and cardiomyopathies, and SPEG interacts functionally with proteins involved in excitation–contraction coupling and sarcomere organization such as RYR2, JPH2, Obscurin, and Titin.

Introduction

SPEG encodes a member of the myosin light chain kinase (MLCK)-related family, expressed predominantly in cardiac and skeletal muscle and in subsets of smooth muscle. Early molecular characterization followed advances from large-scale cDNA projects and proteomic surveys that included contributions from laboratories associated with National Institutes of Health, European Molecular Biology Laboratory, and genome projects like the Human Genome Project. SPEG proteins contain tandem kinase domains homologous to those in MLCK, and modular regions that mediate interactions with cytoskeletal and membrane-associated partners such as Caveolin-3 and Dysferlin.

Structure and Domains

SPEG proteins are large (often >2,700 amino acids) multidomain polypeptides with an architecture conserved across vertebrates. Key structural features include: - Two C-terminal serine/threonine kinase domains related to those in DMPK and MYLK3. - Immunoglobulin-like and fibronectin type III domains resembling motifs in Obscurin and Titin that support sarcomeric scaffolding. - Coiled-coil regions that facilitate oligomerization observed in proteins like Myosin-binding protein C and Nebulin. - PEST-rich segments and phosphorylation sites targeted by kinases such as PKA and CaMKII.

Alternative splicing yields isoforms with differential N-terminal sequences and tissue-specific expression similar to isoform patterns seen in TTN and RYR1. Post-translational modifications include phosphorylation and ubiquitination, which modulate localization to structures analogous to the junctional sarcoplasmic reticulum and transverse tubules characterized in studies of BIN1 and DHPR.

Function and Biochemical Activity

SPEG functions as a kinase and structural scaffold integrating signaling with excitation–contraction coupling. Biochemically, SPEG phosphorylates substrates implicated in calcium handling and sarcomere stability, with reported targets overlapping those of kinases such as AKT1, PKCα, and CAMK2D. Functional roles include: - Regulation of sarcoplasmic reticulum calcium release through modulation of RYR2 and interactions with junctional proteins like JPH2. - Stabilization of the triad and T-tubule architecture via binding partners similar to BIN1 and Caveolin-3. - Phosphorylation-dependent control of myofibrillogenesis through substrates related to Desmin and Myosin heavy chain assembly.

Enzymatic assays demonstrate ATP-dependent phosphorylation with Km values in ranges comparable to other MLCK-family members such as MYLK1. Cellular phenotypes following SPEG knockdown resemble perturbations described for MLCK3 and for perturbations of CASQ2-regulated calcium sequestration.

Clinical Significance and Associated Disorders

Mutations affecting SPEG have been linked to a spectrum of human disorders, principally congenital myopathies and cardiomyopathies often presenting with early-onset dilated cardiomyopathy and skeletal muscle weakness. Clinical associations overlap with phenotypes observed in mutations of RYR1, RYR2, LMNA, TNNT2, and MYH7. Documented presentations include: - Early infantile dilated cardiomyopathy with arrhythmia susceptibility reminiscent of Arrhythmogenic right ventricular cardiomyopathy overlaps. - Centronuclear and myopathic histopathology that shares features with Centronuclear myopathy due to mutations in MTM1 and DNM2. - Respiratory insufficiency and feeding difficulties paralleling severe congenital myopathies described for NEB and RYR1 mutations.

Clinical management follows standards applied to pediatric cardiomyopathy and neuromuscular disease involving centers such as Children's Hospital of Philadelphia and consults with specialists from institutions like Mayo Clinic and Great Ormond Street Hospital.

Genetic Variants and Mutations

Pathogenic variants include homozygous and compound heterozygous loss-of-function mutations, truncating alleles, and missense substitutions within kinase domains that impair catalytic activity, analogous to pathogenic variants in DMPK and MYLK3. Large deletions and splice-site mutations have been reported in cohorts screened by clinical laboratories employing exome sequencing platforms from providers such as Illumina and Thermo Fisher Scientific. Population data from consortia including gnomAD and 1000 Genomes Project provide allele frequencies used to assess variant pathogenicity under standards from ACMG guidelines. Functional assays often correlate genotype with impaired phosphorylation of substrates and altered subcellular localization.

Research Models and Experimental Findings

Model organisms have been instrumental in defining SPEG function. Targeted knockout of the ortholog in Mus musculus yields perinatal lethality or cardiomyopathy depending on allele and background strain, paralleling findings in knockout mouse studies of RYR2 and JPH2. Zebrafish antisense morpholino and CRISPR studies in Danio rerio reproduce cardiac contractility deficits and disrupted sarcomere morphology similar to phenotypes from cmlc2 and tnnt2 perturbations. Cell-based studies using human induced pluripotent stem cell-derived cardiomyocytes from patients recapitulate calcium handling defects and have been used in screens employing small molecules characterized by clinical trials at centers like NIH Clinical Center.

Key experimental findings include biochemical mapping of phosphorylation sites, identification of interacting partners by co-immunoprecipitation and mass spectrometry comparable to approaches used for Obscurin interactome studies, and rescue experiments using kinase-active constructs that restore contractile function in model systems.

Category:Human proteins